Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Intra-Arterial Melphalan Given With Intra-Arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors

NCT00983398 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT00983398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00983398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Intra-Arterial Melphalan Given With Intra-Arterial Carboplatin, Osmotic Blood-Brain Barrier Disruption and Delayed Otoprotective Sodium Thiosulfate for Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Lead sponsor
OHSU Knight Cancer Institute
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 9, 2009
Completion date
December 31, 2022
Enrollment
17 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system embryonal neoplasm, embryonal tumor with multilayered rosettes, c19mc-altered, germ cell tumor, medulloblastoma, medulloepithelioma, primitive neuroectodermal tumor, recurrent childhood central nervous system embryonal neoplasm, recurrent malignant germ cell tumor, recurrent medulloblastoma, recurrent primitive neuroectodermal tumor